Elsevier United States of America United Kingdom

and Privacy Principles which prioritize data privacy, security, and transparency. All user interactions are private, with no data used to train external models. This new release is the latest in a series of solutions from Elsevier that help users discover, analyze and synthesize research using trusted content powered by responsible AI.

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @elsevierconnect.

Media contact
Mathew Pitt-Bailey, Global Communications Director
+44 (0) 7353 890 322
m.pittbailey@elsevier.com

Logo: https://mma.prnewswire.com/media/2717688/5486642/Elsevier_Limited_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/elsevier-launches-pharmapendium-ai-designed-to-support-faster-and-more-reliable-access-to-regulatory-insights-for-drug-development-302543970.html